2013 · 11 citations · 0 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyEnzyme InhibitionLigand BindingMolecular DockingProtein DockingProtein-ligand DockingProtein-protein DockingDipeptidyl PeptidasesDocking ValidationDocking-based Drug DesignIncretin HormonesLigand-protein DockingMolecular Docking For EnzymesMolecular Docking Of InhibitorsProtein-protein-ligand Docking
Dipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9. DPP-IV is a key regulator of incretin hormones, but the functions of other family members are unknown. To determine the importance of selective DPP-IV inhibition for the treatment of diabetes, we conducted molecular docking studies on clinical inhibitors of DPP-IV.